These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

96 related articles for article (PubMed ID: 9603698)

  • 1. Behavioral issues in the efficacy versus effectiveness of pharmacologic agents in the prevention of cardiovascular disease.
    Pearson TA; Feinberg W
    Ann Behav Med; 1997; 19(3):230-8. PubMed ID: 9603698
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The importance of managing cardiovascular risk in the treatment of hypertension: the role of ACE inhibitors and ARBs.
    Pierson CA; Epstein BJ; Roberts ME
    J Am Acad Nurse Pract; 2008 Nov; 20(11):529-38. PubMed ID: 19128336
    [No Abstract]   [Full Text] [Related]  

  • 3. Blood pressure lowering, not vascular mechanism of action, is the primary determinant of clinical outcome.
    Leenen FH
    Can J Cardiol; 2004 Aug; 20 Suppl B():77B-82B. PubMed ID: 15309209
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Adjunctive therapy for acute myocardial infarction.
    Alexander J
    Curr Opin Cardiol; 1997 Sep; 12(5):453-8. PubMed ID: 9352172
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Are angiotensin-converting enzyme inhibitors and angiotensin receptor blockers especially useful for cardiovascular protection?
    Ong HT
    J Am Board Fam Med; 2009; 22(6):686-97. PubMed ID: 19897698
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Is it time to repair a Fairly Fast SAAB Convertible? Testing an evidence-based mnemonic for the secondary prevention of cardiovascular disease.
    Chin J; Fulcher J; Jenkins A; Keech A
    Heart Lung Circ; 2015 May; 24(5):480-7. PubMed ID: 25534901
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Angiotensin II type 1 receptor blockade: high hopes sent back to reality?
    Grothusen A; Divchev D; Luchtefeld M; Schieffer B
    Minerva Cardioangiol; 2009 Dec; 57(6):773-85. PubMed ID: 19942847
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Risk and prevention of diabetic nephropathy].
    Ravera M; Re M; Deferrari G
    G Ital Nefrol; 2007; 24 Suppl 38():13-9. PubMed ID: 17922442
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Choice of antihypertensive drug in the diabetic patient.
    Ong HT; Cheah JS
    MedGenMed; 2005 May; 7(2):74. PubMed ID: 16369452
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The cardiovascular polypill in high-risk patients.
    Lafeber M; Spiering W; Singh K; Guggilla RK; Patil V; Webster R;
    Eur J Prev Cardiol; 2012 Dec; 19(6):1234-42. PubMed ID: 22019908
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Health outcomes associated with various antihypertensive therapies used as first-line agents: a network meta-analysis.
    Psaty BM; Lumley T; Furberg CD; Schellenbaum G; Pahor M; Alderman MH; Weiss NS
    JAMA; 2003 May; 289(19):2534-44. PubMed ID: 12759325
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The 2004 Canadian recommendations for the management of hypertension: Part II--Therapy.
    Khan NA; McAlister FA; Campbell NR; Feldman RD; Rabkin S; Mahon J; Lewanczuk R; Zarnke KB; Hemmelgarn B; Lebel M; Levine M; Herbert C;
    Can J Cardiol; 2004 Jan; 20(1):41-54. PubMed ID: 14968142
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Evolution of the polypill concept and ongoing clinical trials.
    Castellano JM; Sanz G; Fuster V
    Can J Cardiol; 2014 May; 30(5):520-6. PubMed ID: 24786442
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Pharmacological prevention of cardiovascular diseases in general practice].
    Meland E; Ellekjaer H; Gjelsvik B; Kimsås A; Holmen J; Hetlevik I
    Tidsskr Nor Laegeforen; 2000 Sep; 120(22):2643-7. PubMed ID: 11077509
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Efficacy over time of a short overall atherosclerosis management programme on the reduction of cardiovascular risk in patients after an acute coronary syndrome.
    Lafitte M; Pradeau V; Leroux L; Richeboeuf V; Tastet S; Boulon C; Paviot B; Bonnet J; Couffinhal T
    Arch Cardiovasc Dis; 2009 Jan; 102(1):51-8. PubMed ID: 19233109
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Challenging the dogma of high target doses in the treatment of heart failure: is more always better?
    Follath F
    Arch Cardiovasc Dis; 2009 Nov; 102(11):785-9. PubMed ID: 19944395
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Single-pill combinations (SPCs) and treatment of arterial hypertension in Poland. Expert consensus statement of the Polish Society of Hypertension and Polish Cardiac Society Working Group on Cardiovascular Pharmacotherapy.
    Tykarski A; Widecka K; Narkiewicz K; Wożakowska-Kapłon B; Gaciong Z; Grajek S; Grodzicki T; Januszewicz A; Wolf J; Prejbisz A; Kostka-Jeziorny K; Filipiak KJ
    Kardiol Pol; 2017; 75(12):1357-1367. PubMed ID: 29251761
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A review of heart failure management in the elderly population.
    Cheng JW; Nayar M
    Am J Geriatr Pharmacother; 2009 Oct; 7(5):233-49. PubMed ID: 19948300
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The challenge for preventive cardiology.
    Kotseva K; Wood D
    Eur J Cardiovasc Prev Rehabil; 2009 Aug; 16 Suppl 2():S19-23. PubMed ID: 19675431
    [No Abstract]   [Full Text] [Related]  

  • 20. Cardiovascular protection paradigms: is change on the horizon?
    Papademetriou V
    Rev Cardiovasc Med; 2007; 8(4):200-13. PubMed ID: 18192943
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.